N@N

CHTP, ATRC, NCIT, HWAY, CASM, CYTX Are Seasonally Ripe To Go Down In the Next Five Weeks

February 1, 2012 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of CHELSEA THERAPEUTICS INTERNATIONAL, LTD. (NASDAQ:CHTP), ATRICURE INC (NASDAQ:ATRC), NCI Inc (NASDAQ:NCIT), Healthways Inc (NASDAQ:HWAY), CAS MEDICAL SYSTEMS INC (NASDAQ:CASM), CYTORI THERAPEUTICS INC (NASDAQ:CYTX) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go Down:

     Symbol     Company                             Expected Return     Odds                    By The Following Date
     CHTP       CHELSEA THERAPEUTICS INTERNATIONAL, LTD.     -12.72%             85.71% (6 of 7)         Friday, February 10th 2012
     ATRC       ATRICURE INC                        -14.60%             100.00% (6 of 6)        Monday, February 27th 2012
     NCIT       NCI Inc                             -4.04%              100.00% (6 of 6)        Tuesday, February 7th 2012
     HWAY       Healthways Inc                      -3.30%              75.00% (9 of 12)        Monday, February 6th 2012
     CASM       CAS MEDICAL SYSTEMS INC             -8.63%              88.89% (8 of 9)         Wednesday, February 29th 2012
     CYTX       CYTORI THERAPEUTICS INC             -4.49%              100.00% (7 of 7)        Tuesday, February 7th 2012

CHELSEA THERAPEUTICS INTERNATIONAL, LTD. (NASDAQ:CHTP) - Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases. The companys compounds target various prevalent medical conditions, primarily rheumatoid arthritis, psoriasis, cancer, other immunological disorders, and neurogenic orthostatic hypotension associated with Parkinsons disease and other autonomic disorders. It offers Droxidopa, an orally active synthetic precursor of norepinephrine for the treatment of symptomatic neurogenic orthostatic hypotension, freezing gait in Parkinsons disease, and intradialytic hypotension in Japan. The company develops droxidopa in three indications, such as neurogenic orthostatic hypotension, intradialytic hypotension, and fibromyalgia. It also develops a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, such as a portfolio of metabolically inert antifolate molecules, including CH-1504 for the treatment of rheumatoid arthritis that is in a phase II head-to-head clinical trial; and CH-4051, which completed the phase I study designed to determine the maximum tolerated dose based on results of single-ascending and multiple-ascending dose evaluations. In addition, the company develops antifolate program, a platform consisting of a portfolio of dihydroorotate dehydrogenase(DHODH), inhibiting compounds known as the I-3D portfolio, a group of orally active compounds that inhibit the enzyme DHODH for the treatment of autoimmune diseases and transplant rejection. Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina.

ATRICURE INC (NASDAQ:ATRC) - AtriCure, Inc., a medical device company, develops, manufactures, and sells cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac tissue. Its primary product line includes Isolator Synergy Bipolar Radio-Frequency Ablation Clamps for open-heart procedures and minimally invasive procedures; ablation and sensing unit, a compact power generator that delivers bipolar radio-frequency energy; AtriCure switch box, a compact switch box providing the technology needed for the dual pulsing electrodes, and the ability to connect and toggle between multiple RF devices; Isolator multifunctional pen, a disposable RF device enabling surgeons to toggle back and forth between temporary pacing, sensing, stimulation, and ablation; and Coolrail linear ablation device, a disposable linear RF ablation device, which allows physicians to create an expanded cardiac ablation lesion set during minimally invasive procedures. The company also offers cryoablation system, which consists of various reusable and disposable devices, including the Frigitronics CCS-200 product line for cardiac ablation; and Cryo1, a disposable cryothermy ablation probe, as well as AtriClip system, which is designed to exclude the left atrial appendage by implanting the device during open or minimally invasive surgical procedures from the outside of the heart. In addition, it sells enabling technologies, including Lumitip dissector to separate tissues to provide access to key anatomical structures targeted for ablation during general, thoracic, and other surgical procedures; and MicroPace ORLab system, a stimulating, mapping, and recording system enabling physicians to confirm the ablation lines being created are forming electrical barriers or lines of block. The company sells its medical devices to hospitals and medical centers in the United States and internationally. AtriCure, Inc. is headquartered in West Chester, Ohio.

NCI Inc (NASDAQ:NCIT) - NCI, Inc. provides information technology (IT), engineering, logistics, and professional services and solutions to federal government agencies. The company offers enterprise systems management services, which include infrastructure operations and management, outsourcing and managed services, infrastructure consolidation and modernization, public/private cloud computing, application and network management, and network monitoring and performance evaluation, as well as network design, implementation, and migration. NCI also provides network engineering services comprising architecture development and design, disaster response planning and recovery, network configuration, network security evaluation, protocol and topology selection, requirements analysis, routing design, and vulnerability assessment, as well as installation, test, and evaluation. In addition, it offers cybersecurity and information assurance services comprising intrusion detection system/intrusion prevention development, certification and accreditation, policy and procedures development, cybersecurity fusion centers, public key infrastructure implementation, computer forensics, risk and threat assessment, security awareness and training, and security test and evaluation; and software development and systems engineering services consisting of agile and open source software development, database design and management, enterprise portal implementation, legacy system integration, project planning and management, software/systems development, analytical computing solutions, data warehousing/mining, advanced graph analytics, information sharing and collaboration, and high performance and grid computing, as well as integration, test, and evaluation. Further, NCI provides program management, acquisition, and lifecycle support; engineering and logistics services; health IT/medical transformation support; and training and simulation services. The company was incorporated in 2005 and is based in Reston, Virginia.

Healthways Inc (NASDAQ:HWAY) - Healthways, Inc. provides specialized, comprehensive solutions to assist people in maintaining or improving their health and well-being. Its solutions are designed to assist healthy individuals stay healthy, mitigate, and slow the progression of disease associated with family or lifestyle risk factors; and promote the possible health for those already affected by disease. The companys evidence-based programs provide specific and personalized interventions for each individual in a population, irrespective of age or health status, and are delivered to consumers by phone, mail, Internet, and face-to-face interactions. Healthways, Inc. also provides a national, fully accredited complementary and alternative Health Provider Network, and a national Fitness Center Network, offering access to individuals who seek health services outside of, and in conjunction with, the traditional healthcare system. The company delivers its programs to various customers, including health plans, governments, employers, pharmacy benefit managers, and hospitals in the United States and internationally. It operates care enhancement and coaching centers staffed with licensed health professionals, as well as a network of complementary and alternative medicine and chiropractic practitioners. The company was founded in 1981 and is headquartered in Franklin, Tennessee.

CAS MEDICAL SYSTEMS INC (NASDAQ:CASM) - CAS Medical Systems, Inc. develops and manufactures medical devices for non-invasive patient monitoring. The companys FORE-SIGHT Absolute Cerebral Oximeter is a cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for all patients, regardless of age or weight. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition. CAS Medical Systems product lines include the high-acuity monitoring capabilities of the FORE-SIGHT Cerebral Oximeter; and MAXNIBP, a proprietary non-invasive blood pressure measurement technology. The company also offers a line of bedside vital signs monitoring products, and supplies and service, including blood pressure cuffs and products for neonatal intensive care. CAS Medical Systems markets its products through its own sales force, distributors, and manufacturers representatives, as well as through hospital, alternate site, homecare, veterinary, and emergency medical distribution channels. The company was founded in 1984 and is headquartered in Branford, Connecticut.

CYTORI THERAPEUTICS INC (NASDAQ:CYTX) - Cytori Therapeutics, Inc. engages in the development, manufacture, and sale of medical technologies to enable the practice of regenerative medicine. Regenerative medicines focus on repairing or restoring lost or damaged tissue and cell function. The company develops its product pipeline for the treatments of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease, and pelvic health conditions. Its principal products include the Celution family of products, which processes patients' adipose-derived stem and regenerative cells (ADRCs) at the point of care. The Celution family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation. Its core product, the Celution System, provides physicians with clinical grade stem and regenerative cells for use in the cosmetic and reconstructive surgery market. It also intends to offer the PureGraft System in the U.S as a medical device that prepares autologous fat grafts for use in aesthetic body contouring. The company also sells the StemSource family of products worldwide, including in the United States, for research, as well as for the cryopreservation and storage of ADRCs. It offers the StemSource System as a standalone product, or as a part of a comprehensive suite of systems, equipment, and protocols collectively referred to as a StemSource Cell Bank. The company also develops Celution System for applications in cardiovascular disease, wound healing, gastrointestinal disorders, stress urinary incontinence, liver and renal disease spinal disc degeneration, and pelvic health conditions. Cytori Therapeutics has strategic development and manufacturing joint venture agreement, and other related agreements with Olympus Corporation. The company was founded in 1996 and is headquartered in San Diego, California.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641